Nakonezny Paul A, Byerly Matthew J
Center for Biostatistics and Clinical Science and Department of Psychiatry, The University of Texas Southwestern Medical Center, 6363 Forest Park Rd, Suite 651, Dallas, TX 75235-8828, USA.
Schizophr Res. 2006 Feb 15;82(1):107-14. doi: 10.1016/j.schres.2005.10.015. Epub 2005 Dec 22.
To examine the effect of first- vs. second-generation antipsychotics on electronically monitored adherence in outpatients with schizophrenia or schizoaffective disorder.
The sample consisted of 61 outpatients with a DSM-IV diagnosis of schizophrenia or schizoaffective disorder who took either a first-generation (N=25) or second-generation (N=36) oral antipsychotic during study participation. Treatment group designation (first-vs. second-generation antipsychotic) was based on the particular antipsychotic medication the patient was receiving as part of routine care at study entry (i.e., non-random assignment). Adherence to prescribed antipsychotic medication was assessed monthly over a 6-month study period using electronic monitoring (EM) of medication bottle opening. Various participant characteristics were collected at baseline to test for group differences and for potential associations with prospectively measured adherence. The primary data analysis was a mixed-model analysis of repeated measures.
The analysis of EM adherence revealed no significant difference between those taking first-generation (6-month adjusted mean adherence=64.35%) and second-generation antipsychotics (6-month adjusted mean adherence=69.17%; Group effect, p=.29) and no significant Group X Period interaction (p=.13).
There was no statistical difference in EM adherence, over a 6-month period, between patients taking first- and second-generation antipsychotics. However, since the patients were not randomized, conclusions must be interpreted within the context of the quasi-experimental design used in the current study.
探讨第一代与第二代抗精神病药物对精神分裂症或分裂情感性障碍门诊患者电子监测依从性的影响。
样本包括61例门诊患者,他们根据《精神疾病诊断与统计手册》第四版(DSM-IV)诊断为精神分裂症或分裂情感性障碍,在研究期间服用第一代(N = 25)或第二代(N = 36)口服抗精神病药物。治疗组的指定(第一代与第二代抗精神病药物)基于患者在研究开始时作为常规护理一部分所接受的特定抗精神病药物(即非随机分配)。在为期6个月的研究期间,每月使用药瓶开启电子监测(EM)评估对抗精神病药物处方的依从性。在基线时收集各种参与者特征,以测试组间差异以及与前瞻性测量的依从性的潜在关联。主要数据分析是重复测量的混合模型分析。
对EM依从性的分析显示,服用第一代抗精神病药物的患者(6个月调整后平均依从性 = 64.35%)与服用第二代抗精神病药物的患者(6个月调整后平均依从性 = 69.17%;组效应,p = 0.29)之间无显著差异,且无显著的组×时期交互作用(p = 0.13)。
在6个月期间,服用第一代和第二代抗精神病药物的患者在EM依从性方面无统计学差异。然而,由于患者未随机分组,结论必须在本研究使用的准实验设计背景下进行解释。